Bioverativ Shares Look Slightly Overvalued as Near-Term Strength Followed by Longer-Term Uncertainty
We’re maintaining our $52 Bioverativ fair value estimate as we remain bullish on near-term performance, but we are cautious on long-term growth for Eloctate and Alprolix, given significant competitive threats launching over the next few years. We still assume 12% top-line and 11% bottom-line growth through 2021 as Eloctate and Alprolix continue to penetrate the U.S. market (where they were first-to-market among extended half-life therapies) and launch in new geographies including Japan and Latin...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.